Across TCGA pan-cancer cohorts, PURA Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PURA data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PURA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PURA expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

CHOL and LIHC are the cancer types where PURA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LIHC	DFS	Median	III,IV	1.000	0.153	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PURA tumor-vs-normal RNA expression · all PURA data types